Lead Sponsor

EMD Serono

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Rheumatoid arthritis (RA) satisfying American College of Rheumatology (ACR) diagnostic criteria with a disease history of at least one year
•2. Male or female greater than or equal to (\>=)18-years of age at time of informed consent
•3. Active RA as defined by:
•* \>=8 swollen joints (66-joint count),
•* \>=8 tender joints (68-joint count), and
•* C-reactive protein (CRP) \>=10 milligram per liter (mg/L) (central laboratory) and/or erythrocyte sedimentation rate (ESR) \>= to 28 millimeter per hour (mm/h)
•4. Failure of at least one TNFa antagonist therapy (previously or at the time of screening) as specified in the protocol

•1. Any condition, including laboratory findings or findings in the medical history or pre-trial assessments, that in the opinion of the Investigator constitutes a risk or a contraindication for the subject's participation in the trial or that could interfere with the trial objectives, conduct or evaluation
•2. Treatment with biologics aiming at B cell modulation such as rituximab or belimumab within 2 years before study Day 1
•3. Any previous treatment with anakinra (Kineret), abatacept (Orencia) or tocilizumab within 3 months before study Day 1
•4. Use of etanercept (Enbrel) within 28 days before study Day 1, or of infliximab (Remicade) or adalimumab (Humira) within 60 days before study Day 1
•5. Participation in any interventional clinical trial with an unapproved investigational therapy within the 3 months before the start of this study (or within 5 half-lives of the investigated compound before study Day 1, whichever is longer)

Related studies

NCT07171983 · Rheumatoid Arthritis

NCT05869955 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, and more

NCT07558850 · Rheumatoid Arthritis, Dermatomyositis, and more

NCT07536529 · Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), and more

NCT06329401 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, and more

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)